ConferenceEuropean Heart Journal · November 5, 2025
AbstractPurposeAngiotensin receptor-neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduc ...
Full textCite
ConferenceCirculation · November 4, 2025
Introduction/Background:
Multiple clinical trials have demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 Ras) improve symptoms, physical function, and potentially redu ...
Full textCite
ConferenceAm Heart J · November 2025
BACKGROUND: In the PARAGLIDE-HF trial, treatment with sacubitril/valsartan (Sac/Val) was associated with greater reduction in NT-proBNP than valsartan (Val) alone in patients stabilized after an episode of worsening heart failure (HF) with left ventricular ...
Full textLink to itemCite
ConferenceAm Heart J · November 2025
BACKGROUND: PARAGLIDE-HF showed significantly greater reduction in NT-proBNP in patients with LVEF>40% and worsening HF with sacubitril/valsartan (sac/val) vs valsartan (val). The impact of structural abnormalities on the effects of sac/val in this context ...
Full textLink to itemCite
ConferenceEur J Heart Fail · August 2025
AIMS: Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is ...
Full textLink to itemCite
ConferenceCirculation · March 11, 2025
Background:
Osteoprotegerin (OPG), a protein involved in bone metabolism, is associated with left ventricular remodeling and fibrosis. Circulating OPG levels correlate with left ventricular mass index ...
Full textCite
ConferenceCirculation · November 12, 2024
Background:
Growing evidence supports a therapeutic role for ketones in HFrEF. However, no pharmacokinetic (PK) studies are available to guide further investigation, and uncertainty exists regarding u ...
Full textCite
ConferenceCirculation · November 12, 2024
Introduction/Background:
Patients dually eligible for Medicare and Medicaid have higher mortality rates and disparate outcomes for acute cardiovascular conditions. However, the association between dua ...
Full textCite
ConferenceCirculation · November 12, 2024
Introduction/Background:
Understanding the relationship between neighborhood socioeconomic environment and cardiovascular outcomes is important to implement effective quality strategies to ensure heal ...
Full textCite
ConferenceCirculation · November 12, 2024
Background:
In PARAGLIDE-HF, patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) and a recent worsening HF event randomized to sacubitril/valsartan (sac/val) vs val ...
Full textCite
ConferenceCirculation · November 12, 2024
Background:
Patients with HF average >$4000/year in out-of-pocket (OOP) costs for their care, including GDMT. High OOP costs lead to nonadherence and poor outcomes. The OOP costs of GDMT often fluc ...
Full textCite
ConferenceEuropean Heart Journal · October 28, 2024
AbstractBackgroundThe TRANSFORM-HF trial found no significant difference in all-cause mortality and all-cause hospitalization followin ...
Full textCite
ConferenceCirculation · November 7, 2023
Background:
Primary prevention strategies to reduce heart failure (HF) burden are urgently warranted. The Pooled Cohort equations to Prevent HF (PCP-HF) risk score is a validated risk tool that integr ...
Full textCite
ConferenceCirculation · November 7, 2023
Background:
The REHAB-HF randomized, controlled trial demonstrated that a transitional, tailored, progressive rehabilitation intervention improved physical function, 6-minute walk distance, frailty, q ...
Full textCite
ConferenceCirculation · November 7, 2023
Introduction:
TRANSFORM-HF trial showed no significant difference in mortality or hospitalization outcomes in patients randomized to torsemide (T) versus furosemide (F) following a heart failure (HF) ...
Full textCite
ConferenceCirculation · November 7, 2023
Introduction:
In the TRANSFORM HF trial, among patients discharged after hospitalization for heart failure (HF), torsemide compared with furosemide did not result in a significant difference in all-ca ...
Full textCite
ConferenceCirculation · November 7, 2023
Background:
Higher plasma concentrations of angiopoietin 2 (ANGPT2) are associated with higher risk for hospitalization for heart failure (HF) and death in univariate analyses. However, the independen ...
Full textCite
ConferenceCirculation · November 7, 2023
Introduction:
Obesity and hypertension (HTN) are major risk factors for incident heart failure (HF). Obesity is a major cause of HTN; thus, it is difficult to disentangle the impact of each risk facto ...
Full textCite
ConferenceCirculation · November 7, 2023
Background:
The prognostic value of heart rate variability (HRV) in Black Americans (BAs), who have distinct cardiac risk profiles, is not well studied. We aimed to investigate the association between ...
Full textCite
ConferenceCirculation · November 7, 2023
Background:
Electrocardiographic T wave inversion (TWI) has been associated with incident heart failure (HF) in Black Americans without known coronary heart disease (CHD). The aim of this study was to ...
Full textCite
ConferenceCirculation · November 7, 2023
Introduction:
Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all-cause mortality or hospitalization.
...
Full textCite
ConferenceCirculation · November 7, 2023
Background:
Patients (pts) with type 2 diabetes mellitus (T2DM) are at greater risk for major adverse cardiovascular events (MACE; e.g. stroke, myocardial infarction, and cardiovascular death). Given ...
Full textCite
ConferenceCirculation · November 7, 2023
Introduction:
Peripheral artery disease (PAD) and chronic kidney disease (CKD) are common comorbidities in patients with heart failure (HF). Importantly, CKD is associated with a greater risk of incid ...
Full textCite
ConferenceCirculation · November 7, 2023
Background:
Worsening heart failure events (WHFE) affect up to one-third of patients with HFrEF. Vericiguat, the first agent indicated specifically for a WHF population, is a novel soluble guanylate c ...
Full textCite
ConferenceApplied Research in Quality of Life · August 1, 2023
Women with heart failure report worse health-related quality of life on average, than men. This may result from actual differences in care or differing interpretations of and responses to survey questions. We investigated potential gender-based differentia ...
Full textCite
Conference2023 IEEE Signal Processing in Medicine and Biology Symposium Spmb 2023 Proceedings · January 1, 2023
Seismocardiography (SCG) is cardiac-induced chest wall vibration that is often measured non-invasively by accelerometers [1, 2]. SCG is thought to be related to myocardial contractions, valve closures and changes in blood momentum during the cardiac cycle ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Recent type 2 diabetes (T2D) therapeutics have pleiotropic benefits. High throughput proteomic assays offer opportunities to systematically analyze T2D-related cardiometabolic traits and ...
Full textCite
ConferenceCirculation · November 8, 2022
Background:
The New York Heart Association (NYHA) classification remains a cornerstone nomenclature for quantifying health status of patients with heart failure (HF). How this clinician-reported class ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Impaired fatty acid oxidation is common to both kidney and CV complications of diabetes mellitus (DM). We compared metabolic profiles of different cardiorenal trajectories to identify co ...
Full textCite
ConferenceCirculation · November 8, 2022
Background:
Ejection fraction (EF) is a key component of heart failure (HF) categorization, including the newly-proposed HF with mildly reduced EF (HFmrEF) category. The biologic basis of HFmrEF, as a ...
Full textCite
ConferenceCirculation · November 8, 2022
Background:
Heart failure (HF) guidelines recommend assessment of left ventricular ejection fraction (LVEF) to classify patients and guide therapy implementation. However, LVEF alone may be insufficie ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) improves clinical outcomes and quality of life. Optimizing GDMT in the hospital is asso ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Clinical event committee (CEC) adjudication is the gold standard for event reporting in clinical trials. In some instances, investigator-reported events may be an appropriate substitute ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
In February 2021, the US FDA expanded the indication for sacubitril/valsartan (S/V) to include patients with heart failure (HF) with mildly reduced (HFmrEF) or preserved ejection fractio ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Frailty is common in patients with heart failure with reduced ejection fraction (HFrEF) and is independently associated with mortality. Implantable cardiac defibrillator (ICD) therapy is ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Heart failure with preserved ejection fraction (HFpEF) is a common condition with one of its characteristics being exercise intolerance, which contributes to poor quality of life and cli ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Although heart failure (HF) guidelines emphasized dietary sodium restriction, the recommendation was based on limited evidence. We analyzed the impact of dietary sodium restriction on HF ...
Full textCite
ConferenceCirculation · November 8, 2022
Introduction:
Individuals presenting with acute decompensated heart failure (ADHF) have varying response to diuretic therapy and short- and long-term prognosis.
...
Full textCite
ConferenceEur J Heart Fail · November 2022
AIMS: We aimed to investigate the impact of obstructive coronary artery disease (CAD) in patients with acute decompensated heart failure (ADHF), and examine potential differences in prognostic utility for heart failure with reduced (HFrEF) versus preserved ...
Full textLink to itemCite
ConferenceJ Am Heart Assoc · September 7, 2021
Background Contemporary trials of patients with heart failure with reduced ejection fraction (HFrEF) required a recent worsening heart failure (WHF) event for inclusion. We aimed to describe characteristics and outcomes of patients with HFrEF and a recent ...
Full textLink to itemCite
ConferenceCirculation · November 17, 2020
Introduction:
Heart failure (HF) risk and the underlying biological risk factors vary by race. Machine learning (ML) may improve race-specific HF risk prediction but this has not been fully evaluated. ...
Full textCite
ConferenceCirculation · November 17, 2020
Background:
Lower serum vitamin D3 (VitD3) concentration has been associated with cardiovascular disease. However, the associations between serum VitD3 levels and left ventricular (LV) structure and f ...
Full textCite
ConferenceEur J Heart Fail · August 2020
AIMS: Hyperkalaemia and hypokalaemia are common in heart failure and associated with worse outcomes. However, the optimal potassium range is unknown. We sought to determine the optimal range of potassium in patients with heart failure and reduced ejection ...
Full textLink to itemCite
ConferenceDiabetes · June 1, 2020
In EMPA-REG OUTCOME, empagliflozin (EMPA) reduced risk of cardiovascular (CV) death by 38% and hospitalization for heart failure (HHF) by 35% in patients with type 2 diabetes (T2D) and CV disease. We aimed to identify phenotypes of patients with di ...
Full textCite
ConferenceDiabetes · June 1, 2020
GLP-1 RA effects on major kidney outcome in unselected T2D patients at high cardiovascular (CV) risk are modest or neutral. However, GLP-1 RA may provide renal benefit in those at high risk of worsening kidney disease. We examined once-weekly exena ...
Full textCite
ConferenceThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · April 1, 2020
PURPOSE: The use of induction therapy for orthotopic heart transplant (OHT) recipients is inconsistent between centers and there are limited data that explore the association with post-transplant outcomes. We used the International Society for Heart and Lu ...
Full textCite
ConferenceCirculation · March 3, 2020
Introduction:
Obesity is disproportionately prevalent in black populations and strongly associated with heart failure with preserved ejection fraction (HFpEF). An “obesity paradox” or lower mortality ...
Full textCite
ConferenceCirculation · March 3, 2020
Introduction:
Patients with HF have multiple co-existing CV and non-CV comorbidities. The temporal trends in the burden of co-morbidities and associated risk of mortality among patients with acute dec ...
Full textCite
ConferenceDiabetes · June 1, 2019
SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) improve cardiovascular (CV) and renal outcomes through distinct mechanisms. However, evidence is lacking on clinical outcomes in patients treated with both classes. EXSCEL, the cardio ...
Full textCite
ConferenceJ Am Heart Assoc · December 18, 2018
Background We sought to study the prevalence of high-sensitivity troponin and its association with cardiac structure and outcomes in ambulatory and hospitalized patients with heart failure with a preserved ejection fraction ( HF p EF ). Methods and Results ...
Full textLink to itemCite
ConferenceESC Heart Fail · December 2018
AIMS: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with ...
Full textLink to itemCite
ConferenceCirc Heart Fail · November 2018
BACKGROUND: Older hospitalized acute decompensated heart failure (HF) patients have persistently poor outcomes and delayed recovery regardless of ejection fraction (EF). We hypothesized that impairments in physical function, frailty, cognition, mood, and q ...
Full textLink to itemCite
ConferenceDiabetes · July 1, 2018
SGLT2i, empagliflozin and canagliflozin, have been shown to reduce the incidence of major adverse CV events (MACE), all-cause mortality (ACM) and renal events in CV outcomes trials (CVOTs), with robust real-world evidence (RWE) suggesting class eff ...
Full textCite
ConferenceDiabetes · July 1, 2018
Background: EXSCEL was a multinational, randomized, blinded, placebo-controlled, pragmatic CV outcome trial of once-weekly exenatide on the background of usual care. We report exenatide’s impact on estimated glomerular filtration rate (eGFR), new m ...
Full textCite
ConferenceDiabetes · July 1, 2018
Objectives: To evaluate the effect of exenatide 2mg once-weekly vs. placebo in addition to usual care on medical resource use among 14,572 patients with type 2 diabetes enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL), whic ...
Full textCite
ConferenceEur J Heart Fail · March 2018
AIMS: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. METHODS AND RESULTS: We assessed SCD and ventricular arrhythmias in the Acute Study of Clin ...
Full textLink to itemCite
Conference · November 14, 2017
Background: It has previously been shown that patients with chronic kidney disease and heart failure (HF) have progressively lower measures of fitness with declining estimated glomerular filtration rate (eGFR). However, the impact of a structured aerobic e ...
Cite
Conference · 2017
Introduction: Globalization of clinical trials fosters inclusion of patients from higher and lower income countries. The influence of enrolling country income level on heart failure (HF) trial performance is unclear.Methods: Associations between country in ...
Cite
ConferenceJ Card Fail · October 2016
BACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) is more common in women than in men; data characterizing sex differences in the management and outcomes of HFpEF patients presenting to the emergency department (ED) are limited. METHO ...
Full textLink to itemCite
ConferenceEur J Heart Fail · March 2015
AIMS: Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these ...
Full textLink to itemCite
